Cargando…
Potential Psychiatric Uses for MDMA
Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administ...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260336/ https://www.ncbi.nlm.nih.gov/pubmed/27859039 http://dx.doi.org/10.1002/cpt.565 |
_version_ | 1782499388530098176 |
---|---|
author | Yazar‐Klosinski, BB Mithoefer, MC |
author_facet | Yazar‐Klosinski, BB Mithoefer, MC |
author_sort | Yazar‐Klosinski, BB |
collection | PubMed |
description | Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches. |
format | Online Article Text |
id | pubmed-5260336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52603362017-01-26 Potential Psychiatric Uses for MDMA Yazar‐Klosinski, BB Mithoefer, MC Clin Pharmacol Ther Developments Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches. John Wiley and Sons Inc. 2017-01-13 2017-02 /pmc/articles/PMC5260336/ /pubmed/27859039 http://dx.doi.org/10.1002/cpt.565 Text en © 2016, The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Developments Yazar‐Klosinski, BB Mithoefer, MC Potential Psychiatric Uses for MDMA |
title | Potential Psychiatric Uses for MDMA |
title_full | Potential Psychiatric Uses for MDMA |
title_fullStr | Potential Psychiatric Uses for MDMA |
title_full_unstemmed | Potential Psychiatric Uses for MDMA |
title_short | Potential Psychiatric Uses for MDMA |
title_sort | potential psychiatric uses for mdma |
topic | Developments |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260336/ https://www.ncbi.nlm.nih.gov/pubmed/27859039 http://dx.doi.org/10.1002/cpt.565 |
work_keys_str_mv | AT yazarklosinskibb potentialpsychiatricusesformdma AT mithoefermc potentialpsychiatricusesformdma |